Evidence map›Paper›PMID 38521893›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2024

A Phase I, Open-Label, Mass Balance Study of [

Yiming Cheng, Xiaomin Wang, Liangang Liu, Jose Silva, Michael Thomas, Yan Li

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03294603 (A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03294603 phase1completednot on this map

A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of (14C)-CC-220 in Healthy Male Subjects

TypeinterventionalSponsorCelgeneRan2017 to 2017Enrolled6ConditionsHealthy VolunteerArmsCC-220, [14C]
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Yiming ChengClinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA.
Xiaomin WangClinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA.
Liangang LiuGlobal Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USA.
Jose SilvaClinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA.
Michael ThomasClinical Scientist Early Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.
Yan LiClinical Pharmacology, Pharmacometrics, Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA. Yan.Li@bms.com.
Bristol-Myers Squibb (United States) · USBristol-Myers Squibb (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIberdomide is a novel potent cereblon modulator (CELMoD

methodAfter a single dose of radiolabelled [

resultsResults showed that a single oral dose of 1 mg iberdomide was generally well tolerated in healthy subjects. The recovery of [

conclusionBiotransformation of iberdomide in humans included multiple oxidations of the morpholino moiety as well as glutarimide ring hydrolysis of parent and oxidized metabolites and a combination of these pathways. Iberdomide was the predominant component in human plasma, with metabolite M12 being the most prominent circulating metabolite. In excreta, similar iberdomide-derived radioactivity was found in urine and feces. TRIAL REGISTRATION NUMBER: NCT03294603.

Indexed as

Carbon RadioisotopesFecesHealthy VolunteersAdministration, OralAdultArea Under CurveBiotransformationFemaleHumansMaleMiddle AgedYoung AdultCarbon Radioisotopes

Identifiers

PMID38521893
OpenAlexW4393111232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.